Abstract:Overexpression of the polyspecific efflux transporter, P-glycoprotein (P-gp, MDR1, ), is a major mechanism by which cancer cells acquire multidrug resistance (MDR), the resistance to diverse chemotherapeutic drugs. Inhibiting drug transport by P-gp can resensitize cancer cells to chemotherapy, but there are no P-gp inhibitors available to patients. Clinically unsuccessful P-gp inhibitors tend to bind at the pump’s transmembrane drug binding domains and are often P-gp transport substrates, resulting in lowered intracellular concentration of the drug and altered pharmacokinetics. In prior work, we used computationally accelerated drug discovery to identify novel P-gp inhibitors that target the pump’s cytoplasmic nucleotide binding domains. Our first-draft study provided conclusive evidence that the nucleotide binding domains of P-gp are viable targets for drug discovery. Here we develop an enhanced, computationally accelerated drug discovery pipeline that expands upon our prior work by iteratively screening compounds against multiple conformations of P-gp with molecular docking. Targeted molecular dynamics simulations with our homology model of human P-gp were used to generate docking receptors in conformations mimicking a putative drug transport cycle. We offset the increased computational complexity using custom Tanimoto chemical datasets, which maximize the chemical diversity of ligands screened by docking. Using our expanded, virtual-assisted pipeline, we identified nine novel P-gp inhibitors that reverse MDR in two types of P-gp overexpressing human cancer cell lines, reflecting a 13.4% hit rate. Of these inhibitors, all were non-toxic to non-cancerous human cells, and six were not likely to be transport substrates of P-gp. Our novel P-gp inhibitors are chemically diverse and are good candidates for lead optimization. Our results demonstrate that the nucleotide binding domains of P-gp are an underappreciated target in the effort to reverse P-gp-mediated multidrug resistance in cancer.

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

The Flexibility of P-glycoprotein for Its Poly-Specific Drug Binding from Molecular Dynamics Simulations

Simultaneous Binding Mechanism of Multiple Substrates for Multidrug Resistance Transporter P-glycoprotein.

Structure–Function Relationships in the Human P-Glycoprotein (ABCB1): Insights from Molecular Dynamics Simulations

Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function

On Interactions of P-glycoprotein with Various Anti-Tumor Drugs by Binding Free Energy Calculations

Tracing the substrate translocation mechanism in P-glycoprotein

Drug Promiscuity of P-glycoprotein and Its Mechanism of Interaction with Paclitaxel and Doxorubicin.

Interaction of P-glycoprotein with anti-tumor drugs: the site, gate and pathway

Mechanistic insights into P-glycoprotein ligand transport and inhibition revealed by enhanced molecular dynamics simulations

P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers

Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation

Computationally accelerated identification of P-glycoprotein inhibitors

Recent developments of P-glycoprotein inhibitors and its structure-activity relationship (SAR) studies

An Energetically Favorable Ligand Entrance Gate of a Multidrug Transporter Revealed by Partial Nudged Elastic Band Simulations.

Exploring the Dynamics of the ABCB1 Membrane Transporter P-glycoprotein in the Presence of ATP and Active/Non-active Compounds through Molecular Dynamics Simulations

Recent Advances in the Research of P-glycoprotein Inhibitors.

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

Research Advance on P-glycoprotein Inhibitors and the Structure-Activity Relationship

Designing potent inhibitors against the multidrug resistance P-glycoprotein

Multidrug resistance inhibitors targeting P-glycoprotein